期刊文献+

Preparation and Crystal Structures of Two Polymorphic Forms of Bupropion Hydrobromide

Preparation and Crystal Structures of Two Polymorphic Forms of Bupropion Hydrobromide
下载PDF
导出
摘要 Two polymorphic forms (forms I and IV) of antidepressant bupropion hydrobro- mides were prepared and characterized by powder X-ray single-crystal diffractometer. Lots of commercial substances may consist of form I. Form I crystallizes in the triclinic system, space group P1^- with Z= 2, a = 7.6943(8), b = 7.9347(9), c = 13.8558(15) A, a = 85.971(3), β = 85.619(2), γ = 65.974(3)°, V = 769.66(14) A^3, Dc= 1.384 g/cm^3, formula C13H19C1NOBr, F(000) = 328, p = 2.83 mm^-1, the final R = 0.0579 and wR = 0.1282 for 1756 observed reflections with I 〉 2σ(I). Another polymorphic form, IV, belongs to the orthorhombic system, space group Pbca with a = 8.6365(3), b = 12.4167(4), c = 27.7299(9) A, Z = 8, V= 2973.67(17) A^3, Dc= 1.432 g/cm^3, formula C13H19CINOBr, F(000) = 1312,μ = 2.93 mm^-1, the final R = 0.044 and wR = 0.1093 for 2018 observed reflections with I 〉 2σ(I). In the crystal structure of the two polymorphic forms, expected proton transfer from HBr to amino group of bupropion molecule occurs and intramolecular and intermolecular hydrogen bonds N-H…Br are formed. These interactions result in hydrogen-bond dimers in these two forms. The bupropion molecule adopts different conformations in the two investigated solid state modifications. Two polymorphic forms (forms I and IV) of antidepressant bupropion hydrobro- mides were prepared and characterized by powder X-ray single-crystal diffractometer. Lots of commercial substances may consist of form I. Form I crystallizes in the triclinic system, space group P1^- with Z= 2, a = 7.6943(8), b = 7.9347(9), c = 13.8558(15) A, a = 85.971(3), β = 85.619(2), γ = 65.974(3)°, V = 769.66(14) A^3, Dc= 1.384 g/cm^3, formula C13H19C1NOBr, F(000) = 328, p = 2.83 mm^-1, the final R = 0.0579 and wR = 0.1282 for 1756 observed reflections with I 〉 2σ(I). Another polymorphic form, IV, belongs to the orthorhombic system, space group Pbca with a = 8.6365(3), b = 12.4167(4), c = 27.7299(9) A, Z = 8, V= 2973.67(17) A^3, Dc= 1.432 g/cm^3, formula C13H19CINOBr, F(000) = 1312,μ = 2.93 mm^-1, the final R = 0.044 and wR = 0.1093 for 2018 observed reflections with I 〉 2σ(I). In the crystal structure of the two polymorphic forms, expected proton transfer from HBr to amino group of bupropion molecule occurs and intramolecular and intermolecular hydrogen bonds N-H…Br are formed. These interactions result in hydrogen-bond dimers in these two forms. The bupropion molecule adopts different conformations in the two investigated solid state modifications.
出处 《Chinese Journal of Structural Chemistry》 SCIE CAS CSCD 2011年第11期1591-1596,共6页 结构化学(英文)
基金 supported by the Natural Science Foundation of Zhejiang Province (J200801)
关键词 bupropion hydrobromide polymorphic forms crystal structure bupropion hydrobromide, polymorphic forms, crystal structure
  • 相关文献

参考文献10

  • 1Fryer, J. D.; Lukas, R. J. Nancompetitive functional inhibition at diverse, hmnan nicotinic acetylcholine receptor subtypes by bupropion, phencyclidine, and ibogaine. J. Pharmacol. Exp. Ther. 1999, 288, 88-92.
  • 2Stewart, J. J., Berkel, H. J.; Parish, R. C.; Simar, M. R.; Syed, A.; Bocchini, J. A. Jr.; Wilson, J. T.; Manno, J. E. Single-dose pharmacokinetics of bupropion in adolescents, effects of smoking status and gender. ,Z Clin. Pharmacol. 2001, 41,770-778.
  • 3Fang, Q. K.; Han, Z.; Grover, P.; Kessler, D.; Senanayake, C. H.; Wald, S. Cheminform abstract, rapid access to enantiopure bupropion and its major metabolite by stereospecific nucleophilic substitution on an a-ketotriflate. Tetrahedron Asymm. 2000, 11,365%3663.
  • 4Young, J. W. US Pat. WO Patent, A61K31/135, 99/38502. 1999-05-08.
  • 5Maccaroni, E.; Malpezzi, L.; Maseiocehi, N. Structures from powders, bupropion hydrochloride. J. Pharm. Biomed. Analysis 2009, 50, 257-261.
  • 6Froimowitz, M.; George, C. Conformational analysis and a crystal structure of bupropion, an antidepressant with dopamine reuptake blocking activity. J. Chem. Inf. Comput. Sci. 1998, 38,506-510.
  • 7Mississauga, W. O.; Zhou, F.; Davie, F. L.; Toronto, P. N.; Rome, S. T.; Kildare, G. J.; Rome, P. M.; Oakville, M. A. S. CA Pat., US Patent, A61k31/195, 7241802. 200-02-01.
  • 8Materials Data, Inc, Jade, Version 7.5.1, 1224 Concannon Blvd. Livermore, CA 94550, USA.
  • 9Sheldrick, G. M. SHELXS-97, Suite of Programs for Solution and Refinement of Crystal Structure. Acta Co,st. 2008, A64, 112-122.
  • 10Sheldrick, G. M. SHELXL-97, Suite of Programs for Solution and Refinement of Gstal Structure. Acta Gst. Z008, A64, 112-122.

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部